株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

骨粗鬆症治療薬の世界市場 - 産業洞察、動向、見通し、市場機会の分析 2018年~2026年

Osteoporosis Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

発行 Coherent Market Insights 商品コード 785780
出版日 ページ情報 英文 165 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.77円で換算しております。
骨粗鬆症治療薬の世界市場 - 産業洞察、動向、見通し、市場機会の分析 2018年~2026年 Osteoporosis Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
出版日: 2018年08月07日 ページ情報: 英文 165 Pages
概要

骨粗鬆症の新薬の承認と上市が、骨粗鬆症治療薬市場の成長を大きく推進すると予測されています。

当レポートでは、骨粗鬆症治療薬市場を調査し、市場の概要、医薬品タイプ・投与経路・流通経路・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的とその前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場範囲

  • 市場概要
  • レポートの説明
  • 市場の定義と範囲
  • エグゼクティブサマリー
  • 市場スニペット:医薬品タイプ別
  • 市場スニペット:投与経路別
  • 市場スニペット:流通経路別
  • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • マーケットダイナミクス
  • 成長要因
  • 阻害要因
  • 市場機会
  • PEST分析
  • パイプライン分析
  • 製品承認
  • 製品発売
  • 提携・買収
  • ファイブフォース分析

第4章 世界の骨粗鬆症治療薬市場:医薬品タイプ別

  • イントロダクション
    • 市場シェアの分析
    • 前年比成長率の分析
    • セグメント動向
  • ビスホスホネート
  • カルシトニン
  • ホルモン療法
  • 選択的エストロゲン受容体モジュレーター(SERM)
  • 副甲状腺ホルモン関連タンパク質(PTHrP)アナログ
  • ランク配位子(RANKL)抑制剤

第5章 世界の骨粗鬆症治療薬市場:投与経路別

  • イントロダクション
    • 市場シェアの分析
    • 前年比成長率の分析
    • セグメント動向
  • 経口投与
  • 静脈内投与
  • その他

第6章 世界の骨粗鬆症治療薬市場:流通経路別

  • イントロダクション
    • 市場シェアの分析
    • 前年比成長率の分析
    • セグメント動向
  • 病院
  • オンライン薬局
  • 小売薬局

第7章 世界の骨粗鬆症治療薬市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • アフリカ
  • 中東

第8章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
  • 第一三共
  • Amgen Inc.
  • Dr Reddy's Laboratories
  • Mylan Inc.
  • Pfenex Inc.
  • Eli Lilly and Company
  • 旭化成
  • F.Hoffmann La Roche
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co AG
  • GlaxoSmithKline Plc.
  • Allergan plc.
  • Pfizer Inc.

第9章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Osteoporosis is a bone related disease that weakens bones and increase the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis – particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others. The prevalence of osteoporosis is high among the adult population. For instance, according to a report by National Osteoporosis Foundation in 2016, around 54 million adult in the U.S were suffering from osteoporosis or have low bone density.

Market Dynamics

Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over forecast period. For instance, in 2013, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for its drug— DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets—for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Furthermore, osteoporosis commonly affects older adults and increasing geriatric population is expected to lead to high demand for osteoporosis treatment drugs. For instance, according to a report by United Nations Population Fund, people aged 60 years and above accounted for 12.3% of the global population in 2015 and this is expected to reach 22% by 2050 that accounts for 2 billion people.

Key features of the study:

This report provides in-depth analysis of the osteoporosis treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

It profiles leading players in the global osteoporosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

Key companies covered as a part of this study include, EffRx Pharmaceuticals SA, Daiichi Sankyo Company, Limited, Amgen Inc., Dr Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co AG, GlaxoSmithKline Plc., Allergan plc., and Pfizer Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technological up-gradation, market expansion, and marketing tactics

The global osteoporosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the osteoporosis treatment market

Detailed Segmentation:

  • Global Osteoporosis Treatment Market, by Drug Type :
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • Global Osteoporosis Treatment Market, by Route of Administration:
  • Oral
  • Injectable
  • Others
  • Global Osteoporosis Treatment Market, by Distribution Channel:
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • Global Osteoporosis Treatment Market, by Geography:
  • North America
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Europe
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Drug Type:
  • Bisphosphonates
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
  • By Route of Administration:
  • Oral
  • Injectable
  • Others
  • By Distribution Channel
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Teva Pharmaceutical Industries Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Daiichi Sankyo Company Limited.
  • Amgen Inc.
  • Dr Reddy\'s Laboratories
  • Mylan Inc.
  • Pfenex Inc.
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • F.Hoffmann La Roche
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co AG
  • GlaxoSmithKline Plc.
  • Allergan plc.
  • Pfizer Inc.
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • PEST Analysis
    • Pipeline Analysis
    • Product Approval
    • Product Launch
    • Collaboration-Acquisition
    • Porter's Five Forces Analysis

4. Global Osteoporosis Treatment Market, By Drug Type, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Bisphosphonates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Segment Trends
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Selective Estrogen Receptor Modulators (SERMs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Rank Ligand (RANKL) Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

5. Global Osteoporosis Treatment Market, By Route of Administration, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

6. Global Osteoporosis Treatment Market, By Distribution Channel, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)

7. Global Osteoporosis Treatment Market, By Region, 2016 - 2026 (US$ Bn)

    • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
    • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Daiichi Sankyo Company Limited.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Dr Reddy's Laboratories
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Mylan Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfenex Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Asahi Kasei Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F.Hoffmann La Roche
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • EffRx Pharmaceuticals SA
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allergan plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact